DENMARK – The European Commission has granted marketing authorization of Lundbeck’s anti-Calcitonin Gene Related Protein (Anti-CGRP) antibody Vyepti (eptinezumab) in the European Union (EU) for the prophylactic treatment of migraine…
Read MoreLundbeck’s Vyepti scores EC approval for migraine prevention
